Stocks to Watch: Oracle, Acelyrin, Humacyte
By Ben Glickman
Oracle reported fiscal first-quarter growth in its cloud business slowed sequentially and compared to the year-ago quarter. Oracle's total revenue grew 9% to $12.45 billion, but was in line with analysts' estimates, according to FactSet. Shares sink 9% to $115.31 after-hours on Monday.
Acelyrin reported that one of its skin drug candidate's primary endpoint didn't meet statistical significance by week 16 of a Phase 2b/3 trial. The company, which went public in May, said it still had a strong financial position and expects its cash to fund operations through important milestones for other existing drug candidates. Shares fall 61% to $10.98 after-hours.
Humacyte said it would announce top-line data from its Phase 2/3 trial evaluating the use of implantable bioengineered human tissue in vascular trauma repair on Tuesday morning. The biotechnology company said Monday a separate study of its technology in the treatment of chronic limb-threatening ischemia yielded promising results. Shares rise 7.6% to $3.98 after-hours.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
September 11, 2023 19:48 ET (23:48 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks